Latest Olanzapine Stories
INDIANAPOLIS, July 22 /PRNewswire-FirstCall/ -- Nine percent revenue growth driven by higher volume continues strong trend for the year.21 percent of Q2 revenue invested in R&D to advance pipeline of nearly 70 potential new medicines in clinical development.Ongoing cost-containment efforts support double-digit growth in operating income.Q2 earnings per share grow to $1.22 (reported), or $1.24 (non-GAAP).2010 earnings per share guidance range raised to $4.44 to $4.59 (reported), or $4.50...
All the major groups of medications for schizophrenia turn up the volume of a brain signal known to be muted in individuals with this psychiatric disorder â€” a signal that also can be influenced by diet.
INDIANAPOLIS, April 19 /PRNewswire-FirstCall/ -- Nine percent revenue growth driven by higher volumeWeaker dollar versus prior periods results in decreased gross margin percentQ1 earnings per share of $1.13 (reported), or $1.18 (non-GAAP), includes $.12 per share reduction due to the impact of U.S.
WALTHAM, Mass., April 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed psychiatrists say that the decrease in severity of manic symptoms is the attribute that most influences their prescribing decisions in bipolar mania.
WALTHAM, Mass., April 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Janssen's Invega Sustenna earns Decision Resources' proprietary clinical gold standard status for the treatment of schizophrenia in 2013.
INDIANAPOLIS, March 17 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today issued a statement and details regarding the stolen company products from its distribution operations in Enfield, Connecticut on Sunday, March 14. Lilly is working with the U.S.
RAMAT GAN, Israel, February 16, 2010 /PRNewswire-FirstCall/ -- Obecure Ltd (http://www.obecure.com)., a subsidiary of Bio-Light Israeli Life Science Investments Ltd.
A new study concludes that many doctors appear to have largely ignored a Food and Drug Administration warning to screen users of new antipsychotic drugs for high blood sugar and cholesterol, which poses risks to their health and raises questions about the efficacy of warning protocols in general.
A study published today in the Archives of Internal Medicine examines the impact of a safety warning issued by the Food and Drug Administration for commonly prescribed antipsychotic medications.
The use of atypical antipsychotics to treat elderly patients with dementia appears to have decreased following a 2005 Food and Drug Administration (FDA) advisory regarding the risks of these medications in this population.